{"cursor":"16357","size":15,"audio":[],"currentlang":"en","article":"{{Drugbox\n| verifiedrevid = 461118063 IUPAC_name = (4aS,6R,8aS)- 5,6,9,10,11,12- hexahydro-\n| 3-methoxy- 11-methyl- 4aH- [1]benzofuro[3a,3,2-ef] [2] benzazepin- 6-ol image\n| = Galantamine.svg width = 175\n\n\n| tradename = Razadyne Drugs.com = MedlinePlus = a699058 pregnancy_category = B\n| legal_status = Rx routes_of_administration = Oral\n\n\n| bioavailability = 80 to 100% protein_bound = 18% metabolism = Hepatic\n| partially CYP450:CYP2D6/3A4 substrate elimination_half-life = 7 hours\n| excretion = Renal (95%, of which 32% unchanged), fecal (5%)\n\n\n| CASNo_Ref = CAS_number_Ref = CAS_number = 357-70-0 ATC_prefix = N06 ATC_suffix\n| = DA04 PubChem = 9651 DrugBank_Ref = DrugBank = DB00674 ChemSpiderID_Ref =\n| ChemSpiderID = 9272 UNII_Ref = UNII = 0D3Q044KCA KEGG_Ref = KEGG = D04292\n| ChEBI_Ref = ChEBI = 42944 ChEMBL_Ref = ChEMBL = 659\n\n\n| C=17 | H=21 | N=1 | O=3 molecular_weight = 287.354Â g/mol smiles =\n| O(c2c1O[C@H]4C[C@@H](O)/C=C\\[C@@]43c1c(cc2)CN(C)CC3)C InChI = 1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-\n| 18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1 InChIKey = ASUTZQLVASHGKV-\n| JDFRZJQEBY StdInChI_Ref = StdInChI = 1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-\n| 18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1 StdInChIKey_Ref =\n| StdInChIKey = ASUTZQLVASHGKV-JDFRZJQESA-N melting_point = 126.5\n}}\n\n'Galantamine' ('Nivalin', 'Razadyne', 'Razadyne ER', 'Reminyl', 'Lycoremine') is\nused for the treatment of mild to moderate Alzheimer's disease and various other\nmemory impairments, in particular those of vascular origin. It is an alkaloid\nthat is obtained synthetically or from the bulbs and flowers of Galanthus\ncaucasicus (Caucasian snowdrop, Voronov's snowdrop), Galanthus woronowii\n(Amaryllidaceae) and related genera like Narcissus (daffodil)), [http://www.nnfcc.co.uk/publications/nnfcc-project-factsheet-\nsustainable-production-of-the-natural-product-galanthamine-defra-nf0612 NNFCC\nProject Factsheet: Sustainable Production of the Natural Product Galanthamine\n(Defra), NF0612] Leucojum (snowflake), and Lycoris including [[Lycoris\nradiata]] (Red Spider Lily).\n\nStudies of usage in modern medicine began in the Soviet Union in the 1950s. The\nactive ingredient was extracted, identified, and studied, in particular in\nrelation to its acetylcholinesterase (AChE)-inhibiting properties. The bulk of\nthe work was carried out by Soviet pharmacologists Mashkovsky and Kruglikova-\nLvova, beginning in 1951. [http://www.pharmj.com/editorial/20041218/christm-\nas/p905alzheimers.html Snowdrops: the heralds of spring and a modern drug for\nAlzheimer's disease] The work of Mashkovsky and Kruglikova-Lvova was the\nfirst published work that demonstrated the AChE-inhibiting properties of\ngalantamine. Mashkovsky MD, Kruglikova-Lvova RP. On the pharmacology of the\nnew alkaloid galantamine. Farmakologia Toxicologia (Moscow) 1951;14:27-30 (in\nRussian).\n\nThe first industrial process was developed in Bulgaria by prof. Paskov in 1959\n(Nivalin, Sopharma) from a species traditionally used as a popular medicine in\nEastern Europe, and, thus, the idea for developing a medicine from these species\nseems to be based on the local use (i.e., an ethnobotany-driven drug\ndiscovery).\n\nGalantamine has been used for decades in Eastern Europe and Russia for various\nindications such as treatment of myasthenia, myopathy, and sensory and motor\ndysfunction associated with disorders of the central nervous system. In the US,\nit is FDA approved for the treatment of Alzheimer's disease.\n\nIt is available in both a prescription form and as an over the counter\nsupplement.\n","linknr":947,"url":"galanthamine","recorded":1362512884,"links":44,"instances":["united_states","medicine"],"pdf":["http://www.ortho-mcneilneurologics.com/ortho-mcneilneurologics/shared/pi/razadyne.pdf","http://lucidconsciousness.com/wp-content/uploads/2009/01/Pharmacological-Induction-of-Lucid-Dreams.pdf","http://lucidconsciousness.com/wp-content/uploads/2009/01/Pharmacological-Induction-of-Lucid-Dreams.pdf","http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126138.pdf","http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126138.pdf"],"categories":["Acetylcholinesterase inhibitors","Antidementia agents","Nootropics","Phenol ethers","Alcohols","Benzazepines","Janssen Pharmaceutica"],"headings":["Pharmacology","Pharmacokinetics","Metabolism","Clinical use","Other uses","Caution","Total synthesis","References","External links"],"image":["//upload.wikimedia.org/wikipedia/commons/thumb/7/71/Galantamine.svg/175px-Galantamine.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png","//bits.wikimedia.org/static-1.21wmf10/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.21wmf10/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[["food_and_drug_administration","united_states"],["syncope","medicine"]],"members":["food_and_drug_administration","syncope"],"related":["Liver","Cytochrome_P450_oxidase","CYP2D6","CYP3A4","Kidney","Alzheimer's_disease","Memory","Vascular","Alkaloid","Snowdrop","Daffodil","Medicine","Soviet_Union","Acetylcholinesterase","Soviet_Union","Bulgaria","Dimitar_Paskov","Nivalin","Sopharma","Eastern_Europe","Ethnobotany","Russia","Competitive_inhibition","Cholinesterase_inhibitor","Acetylcholine","X-ray_crystallography","Nicotinic_acetylcholine_receptor","Bioavailability","Elimination_half-life","Acetylcholinesterase","Plasma_protein_binding","CYP2D6","CYP3A4","Poor_metabolizer","Multi-infarct_dementia","Adverse_drug_reaction","Gastrointestinal_tract","Lucid_dream","Out-of-body_experience","Meditation","Choline_bitartrate","Alpha-GPC","Nootropic","Insomnia","Huperzine_A","Nootropic","Food_and_Drug_Administration_(United_States)","Mild_cognitive_impairment","Bradycardia","Syncope_(medicine)","Total_synthesis"]}